Australian Specialized REITs Stock News

ASX:EDV
ASX:EDVConsumer Retailing

Endeavour Resets Pinnacle Drinks As Share Price Trails Valuation Estimates

Endeavour Group (ASX:EDV) is restructuring its Pinnacle Drinks business, including a review of its winery footprint and operations. The group plans to sell the Oakridge wine brand and exit or sell other non core winery assets. Winery operations are being consolidated to focus on a tighter set of beverage assets within the Pinnacle portfolio. For investors watching Endeavour Group, this reset follows a period of share price weakness. The stock closed at A$2.86, with the share price down 7.4%...
ASX:AEF
ASX:AEFCapital Markets

ASX Dividend Stocks Featuring Australian Ethical Investment

As Australian shares face a slight retreat, influenced by Wall Street's recent cooling and local inflation concerns, investors are keenly watching how these factors might impact dividend stocks on the ASX. In this environment, identifying robust dividend stocks like Australian Ethical Investment can provide stability and potential income for portfolios amidst market fluctuations.
ASX:FRS
ASX:FRSMetals and Mining

ASX Growth Stocks With Insider Ownership Up To 37%

As Australian shares face a potential retreat, reflecting Wall Street's recent cooling, investors are keenly observing the interplay between local economic indicators and global market trends. In this fluctuating environment, growth companies with substantial insider ownership can be particularly appealing as they often signal confidence from those who know the business best.
ASX:EDU
ASX:EDUConsumer Services

3 Promising ASX Penny Stocks With Market Caps Under A$700M

Australian shares are set for a slight retreat, influenced by market dynamics both locally and internationally, with Wall Street's recent cooling after hitting new highs. In the context of these fluctuating markets, penny stocks—though an older term—remain relevant as they often represent smaller or newer companies with potential for growth at accessible price points. By focusing on those with strong financial health and solid fundamentals, investors can uncover promising opportunities within...
ASX:EOS
ASX:EOSAerospace & Defense

Electro Optic Systems (ASX:EOS) Is Up 19.5% After Funding MARSS Deal And Defence Board Refresh – What's Changed

Electro Optic Systems Holdings has recently raised A$150,000,000 via an institutional placement, A$40,000,000 through a follow-on offering, and plans an additional A$25,000,000 Share Purchase Plan to help fund the acquisition of UK counter-drone and autonomous maritime specialist MARSS, while also adding retired senior Australian Defence leaders Catherine Roberts and Kathryn Toohey to its board. This combination of sizeable equity raising, a defence-focused acquisition, and governance...
ASX:GMG
ASX:GMGIndustrial REITs

Goodman Group (ASX:GMG) Valuation Check After New Sagamihara Data Centre Partnership

Goodman Group (ASX:GMG) has been appointed lead development partner for a proposed data centre campus in Sagamihara City, Kanagawa Prefecture, Japan, highlighting its growing role in digital infrastructure and sustainability focused projects. See our latest analysis for Goodman Group. The Sagamihara announcement comes as Goodman Group trades at A$30.77, with a 30 day share price return of 6.47% and a 90 day share price return of 6.32%. The 3 year total shareholder return of 60.30% contrasts...
ASX:NUF
ASX:NUFChemicals

Nufarm (ASX:NUF) H1 Profit Of A$28m Tests Long Running Loss Concerns

Nufarm (ASX:NUF) opened H1 2026 with revenue of A$1.7 billion and basic EPS of A$0.07, alongside net income of A$28.0 million. Over the recent half yearly periods, the company has seen revenue move from A$1.8 billion and EPS of A$0.05 in H1 2025 to A$1.6 billion with EPS declining to A$0.54 in H2 2025, before landing at the latest H1 2026 levels. This gives investors a clearer read on how margins are tracking quarter to quarter. Against a backdrop of trailing twelve month losses and analyst...
ASX:SGLLV
ASX:SGLLVFood

3 Dividend Fortresses With High Yields And Underpriced Earnings Power

Income investors are being pulled in several directions by stubborn inflation signals, shifting rate expectations and uneven consumer data across major economies. In this kind of cross‑current, high yield alone is not enough; durability matters just as much as payout. That is exactly what the Dividend Fortresses screener is built to target, focusing on stocks with dividend yields of 5% or more that aim to hold up when conditions get choppy. In this article, you will see three stocks from that...
ASX:SHV
ASX:SHVFood

Select Harvests H1 2026 Margin Slippage Tests Bullish Earnings Narratives

Fresh from its H1 2026 update, Select Harvests (ASX:SHV) is under the spotlight as you weigh recent revenue and EPS trends against the stock’s A$3.90 share price and what they might signal for profitability. The company has seen half year revenue shift from A$226.4 million in H2 2024 to A$293.8 million in H2 2025, while basic EPS over the same periods moved from A$0.03 to A$0.02, setting up a mixed read on earnings momentum. With trailing 12 month net profit margin at 8.4% versus 8.7% in the...
ASX:GDG
ASX:GDGInsurance

ASX Penny Stocks With Market Caps Under A$3B To Consider

Australian shares are poised for a slight retreat, influenced by Wall Street's recent cooling and ongoing global economic discussions. Despite the fluctuating market conditions, penny stocks—often overlooked due to their smaller size or newer status—can still present valuable opportunities when backed by solid financials. In this article, we explore several promising Australian penny stocks that combine financial strength with potential for long-term growth.
ASX:TLX
ASX:TLXBiotechs

How Investors Are Reacting To Telix Pharmaceuticals (ASX:TLX) Glioblastoma Trial Enrolment Milestone

Earlier in May 2026, Telix Pharmaceuticals reported that its Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblastoma completed enrolment, with no dose-limiting toxicities observed so far at doses up to 10GBq alongside standard-of-care therapy. This progress, together with ongoing Phase 3 evaluation of TLX101-Tx as the first radiopharmaceutical therapy to reach this stage in glioblastoma, highlights Telix’s attempt to build a differentiated neuro-oncology franchise using...
ASX:LYC
ASX:LYCMetals and Mining

Low Risk Leaders Quietly Powering Gold And Rare Earths

Markets are being pulled in different directions by geopolitics, energy prices and shifting interest rate expectations, and it can feel hard to know where to focus. One approach is to build around companies that aim to be resilient when conditions change. Our Low-Risk Leaders screener targets stocks with strong balance sheets and low model risk scores, designed to help reduce volatility while still keeping you in the market. In this article, you will see three stocks from that screener and...